The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

In 2019, the FDA approved Spravato, "a nasal spray derived from ketamine," for treating severe depression. "But that approval came with strict guardrails to ensure patient safety," added the Post ...

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...

This is because the Food and Drug Administration (FDA) only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine.

HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...